Helix BioPharma Corp. To Present At Precision Lung Cancer World R&D Summit

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that Dr. Heman Chao, Helix’s CSO, will be presenting: Therapeutic Strategy Against Tumor Acidity Induced Immune-Suppression: L-DOS47 a Clinical Candidate for Lung
Cancer at the Precision Lung Cancer World R&D Summit being held on September 13th and 14th, 2016 at the Royal Sonesta Boston hotel in Boston, Massachusetts.